At the same time as the decline, there are also problems with product quality. Among them, the adverse reactions of Danhong injection occurred frequently; Naoxintong capsule was also exposed by the Food and Drug Administration because it failed to detect the content of tanshinone IIA. Not only that, other popular drugs such as Xueshuantong and Xuesaitong are also under key monitoring.
Can such a strenuous step-length pharmaceutical still call the original slogan? Obviously, the step size at this moment is no longer the confidence of four years ago. How can an unclear future make investors expect the “step of the world” in the slogan?
04Postscript
The relationship between a listed company and the capital market is like a boat and water, and water can carry a boat and overturn it. Some companies seize the opportunity of listing to complete large-scale expansion, or strategic transformation, becoming a typical representative of industry development. From this perspective, Buchan Pharmaceutical, which holds a good brand, has lost itself in the capital market.
Chinese pharmaceutical companies are at a crossroads of brand-new development. Innovative medicine is the main track for future development. This competition is no longer marketing intensity but technical thickness. Therefore, the richness of innovative product pipelines, hard indicators of R&D investment, keen judgment on market changes, and the shaping of company brand and product reputation are the indicators to measure the competitiveness of pharmaceutical companies.